Kamada (NASDAQ:KMDA) Stock Rating Lowered by Wall Street Zen

Kamada (NASDAQ:KMDA) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also recently issued research reports about the stock. Stifel Nicolaus set a $11.00 price target on shares of Kamada in a research report on Wednesday. Benchmark reissued a “buy” rating on shares of Kamada in a research note on Thursday. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. Finally, HC Wainwright upped their price target on Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $13.00.

Kamada Trading Up 0.1%

KMDA opened at $8.70 on Friday. Kamada has a 1-year low of $5.54 and a 1-year high of $9.35. The company has a market cap of $500.34 million, a price-to-earnings ratio of 24.86, a PEG ratio of 0.76 and a beta of 0.94. The company’s fifty day moving average price is $8.44 and its two-hundred day moving average price is $7.46.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, March 11th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The business had revenue of $44.68 million for the quarter, compared to analyst estimates of $145.07 million. Kamada had a net margin of 11.19% and a return on equity of 7.72%. As a group, equities analysts forecast that Kamada will post 0.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kamada

A number of hedge funds and other institutional investors have recently modified their holdings of KMDA. Essex Investment Management Co. LLC increased its position in shares of Kamada by 22.4% during the third quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock valued at $2,751,000 after acquiring an additional 72,602 shares during the last quarter. Acadian Asset Management LLC grew its stake in Kamada by 3.1% in the 2nd quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock valued at $2,053,000 after purchasing an additional 7,925 shares during the period. Simplicity Wealth LLC bought a new position in Kamada in the 3rd quarter valued at $70,000. Huntleigh Advisors Inc. increased its position in shares of Kamada by 4.3% during the 3rd quarter. Huntleigh Advisors Inc. now owns 141,562 shares of the biotechnology company’s stock valued at $982,000 after purchasing an additional 5,786 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Kamada during the 4th quarter valued at $103,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.